Across TCGA pan-cancer cohorts, MT-ND3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MT-ND3 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher MT-ND3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MT-ND3 expression acts as an unfavorable survival marker, although some lineages such as OV show a favorable association.

OV, LSCC, and GBM are the cancer types where MT-ND3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Tertile	All	0.982	0.762	.046	8	view →
LSCC	DFS	Median	All	0.505	0.952	.006	8	view →
GBM	OS	Median	All	0.408	0.671	.015	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: MT-ND3 tumor-vs-normal RNA expression · all MT-ND3 data types